Actively Recruiting
Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer
Led by University of Aberdeen · Updated on 2023-05-16
450
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of gut bacteria in patients with pelvic cancers, including bladder, prostate, cervical, ovarian, womb, and colorectal cancers. The study aims to better understand how these bacteria influence responses to cancer treatments like radiotherapy and chemotherapy. This observational study explores the interactions between gut microbiota and cancer therapies to improve knowledge of bacterial effects during treatment. Participants will provide stool samples before starting their cancer treatments, such as chemotherapy, radiotherapy, or surgery. In some colorectal cancer cases, samples from the colon may also be collected during surgery. Blood samples may be taken to analyze inflammatory and immune markers. Participants may also complete food questionnaires to assess their diet before sample collection. Collected samples will be processed and analyzed using genetic sequencing and metabolite testing to profile the gut bacteria and their activity. Throughout the study, clinical data including tumor responses and treatment side effects will be gathered from patient records and routine follow-up questionnaires. The research team will analyze the association between gut bacteria profiles and treatment outcomes. Data will be stored securely and may be used for future research with appropriate approvals. The study plans to recruit participants over an 18-month period and follow their response to therapy, aiming to improve future cancer treatment strategies.
CONDITIONS
Brief Title
Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients willing to consent
- Patients aged 16 years or older
- Patients being treated in NHS Grampian for a pelvic cancer (colorectal, urological, or gynaecological)
You will not qualify if you...
- Patients not willing to consent to participate
- Patients with malignancies from other sources or anatomical locations
- Patients who do not understand the study sufficiently to provide appropriate consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or video teleconference)
Duration - Up to 1 week before starting cancer therapy
Participants provide faecal and blood samples before their next cancer therapy. They may also choose to complete optional dietary questionnaires. Samples are collected during clinical appointments or dropped off at a designated centre.
1 to 2 visits depending on sample drop-off and clinical appointments
Duration - Up to 18 months
Participants' clinical data and outcomes are observed over time to study correlations between microbiota and cancer therapy response. No interventions are administered as part of this observational study.
Data collected through routine clinical follow-up visits
Trial Site Locations
Total: 1 location
1
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Actively Recruiting
Research Team
G
George Ramsay, FRCS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here